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ABSTRACT
Objective: The objective of the study is to find out the resistance pattern of pathogenic organisms isolated from intra-abdominal infection (IAI).
Methods: A total of 500 samples were collected from suspected IAIs of patients reporting to the hospital and cultured. Identification of the isolates 
was done using standard identification protocol. Antimicrobial susceptibility was performed by Kirby-Bauer disc diffusion method and interpretation 
was done using Central Laboratory Standard Institute guidelines.
Results: Out of 500 samples, 170 were culture positive and 330 showed no growth. Gram-negative organisms (n=127) outnumbered the Gram-positive 
organisms (n=23). Among the Gram-negative organisms, Escherichia coli (n=67) was the most commonly isolated bacilli followed by Klebsiella sp. 
(n=32), Pseudomonas sp. (n=25), Acinetobacter baumannii (n=18), and Klebsiella oxytoca (n=05). Among Gram-positive organisms Staphylococcus 
aureus (n=17) and Enterococcus spp (n=06) isolates of were grown in culture. Among Gram-negative bacilli, Imipenem followed by Gentamicin was 
the most effective drug but in Acinetobacter spp. The second most effective drug was Tigecycline. Among Gram-positive isolates, Linezolid was the 
most effective drug.
Conclusion: Prompt starting of empirical antimicrobials based on the local susceptibility pattern, followed by modification of treatment in accordance 
with the antimicrobial susceptibility report can significantly reduce the morbidity and the mortality associated with IAIs.
Keywords: Intra-abdominal infections, Methicillin-resistant Staphylococcus aureus, Empirical antimicrobials, Emerging resistance, Gram-negative 
organisms, Gram-positive organisms.
INTRODUCTION
Intra-abdominal infections (IAI’s) are associated with significant 
morbidity and mortality and common cause of hospitalized patients [1]. 
IAIs is a wide term that encompasses a number of infectious processes 
which include peritonitis, diverticulitis, cholecystitis, cholangitis, 
pancreatitis, chronic liver failure, and intestinal perforation [2]. 
According to the Infectious Diseases Society of America, complicated 
IAIs is defined as an infection that extends beyond the wall of a hollow 
viscous of source into the abdominal cavity while being related with 
an abscess or peritonitis [3]. Etiology of the organism responsible for 
the IAI can be conditional, based on the location of the organ originally 
infected, since the residential Gastrointestinal flora is typically the 
cause in the IAIs. For example, infections occurring in the stomach 
and proximal small intestine mostly involve Gram-positive organisms, 
whereas those in the distal small intestine involve more Gram-negative 
aerobic and facultative anaerobic bacilli. Even more distally, infections 
in the colon consist mainly of obligate anaerobic organisms [3,4]. 
Management of IAIs requires the involvement of multiple modalities 
such as surgeries as well as treatment with antimicrobials [5]. Hospital-
acquired IAIs are associated with higher mortality rates because 
of compromised patient’s immunity due to underlying illness and 
infections with multidrug-resistant organisms [1]. Antimicrobial 
management plays a vital role in critically ill patients with IAIs as 
selection of wrong antimicrobial can cause therapeutically failure which 
can lead to further mortality rate [6]. Initially, empirical therapy should 
be started based on the most frequently isolated organism and local 
pattern of antibiotic susceptibility, which should be modified to specific 
antimicrobials after receiving the microbiology report of antimicrobial 
susceptibility of the isolated organism [7]. Growing emergence of 
resistance to multiple drugs and dearth of local data on antimicrobial 
resistance pattern of IAIs is the cause of concern for the management 
of IAIs [8]. By keeping in mind the above facts, the present study was 
planned to determine the resistance pattern of pathogenic organisms 
isolated from IAIs.
METHODS
The present study was conducted for the duration of 2 years, 
i.e., 2018– 2020 to determine the bacteriological profile and 
antimicrobial susceptibility pattern of isolates from the samples 
received from IAIs in the department of Microbiology, MMIMSR, 
Mullana, Ambala, Haryana, India. Ethical clearance for the study was 
taken from Institutional Ethical Committee.
Processing of samples
A total of 500 samples, like - ascetic fluid, bile, pus from intra-
abdominal cavity, were obtained from patients suffering from IAIs such 
as peritonitis, cholithiasis, appendicitis, pancreatitis, liver abscess. All 
the samples were cultured on Blood agar and MacConkey agar and 
incubated at 37°C for 18–24 h and gram staining was performed on each 
sample. Identification of isolates was done using standard identification 
protocol (Mackey and McCartney) and other relevant biochemical 
tests as appropriate for isolates. Antimicrobial susceptibility testing 
was done by Kirby-Bauer disc diffusion methods and as per Central 
Laboratory Standard Institute (CLSI), 2018 guidelines [9-11].
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Antibiotic susceptibility tests
Antimicrobial sensitivity pattern of the isolates was performed using 
Kirby-Bauer disk diffusion method and interpreted according to 
guidelines of CLSI. Antimicrobial sensitivity testing for Gram-negative 
isolates was applied using:
a. For Escherichia coli, Klebsiella spp. and Klebsiella oxytoca: 
Ciprofloxacin (5 µg), Piperacillin-Tazobactum (100/10 µg), Amikacin 
(30 µg), Ceftrixone (30 µg), Cefuroxime (30 µg), Cefotaxime (30 µg), 
Gentamicin (10 µg), Imipenem (10 µg), Meropenem (10 µg), Cefepime 
(30 µg), Trimethoprim-Sulphomethoxazole (1.25/23.75 µg)
b. For Pseudomonas spp. and Acinetobacter baumanii: Ciprofloxacin 
(5 µg), Levofloxacin (5 µg), Gentamicin (10 µg), Imipenem (10 µg), 
Meropenem (10 µg), Cefepime (30 µg), Ceftazidime (30 µg), 
Netilimicin (30 µg), Tobramycin (10 µg), and Ticarcillin-Clavulanic 
acid (75/10 µg).
In addition, Amikacin (30 µg) was also tested against Pseudomonas spp. 
For A. baumanii Ceftriaxone (30 µg), Trimethoprim-Sulphomethoxazole 
(1.25/23.75 µg), Piperacillin-Tazobactum (100/10 µg), Minocycline 
(30 µg), and Tigecycline (15 µg) were also additionally tested.
Antibiotics applied for Gram-positive isolates were: Ampicillin (10 µg), 
Erythromycin (15 µg), Ciprofloxacin (5 µg), Levofloxacin (5 µg), 
Tetracycline (30 µg), and Linezolid (30 µg).
Additional antibiotics tested against Staphylococcus aureus 
were Penicillin (10 units), Cefoxitin (30 µg), Clindamycin (2 µg), 
Trimethoprim-Sulfamethoxazole (1.25/23.75 µg), Minocycline (30 µg), 
and Doxycycline (30 µg).
Additional antibiotics tested against Enterococcus spp. was High-level 
Gentamicin (120 µg).
Screening for Methicillin-resistance in S. aureus was done using 
cefoxitin disc as per CLSI guidelines.
RESULTS
Out of 500 samples collected from clinically suspected cases of IAIs, 
405 were indoor patients while 95 were outdoor patients (Table 1). All 
500 samples were cultured out of which, 330 showed no growth while 
growth was obtained in 170 samples. Out of 170 samples, 23 samples 
showed growth of Gram-positive cocci, in which S. aureus (n=17) 
were predominant followed by Enterococcus spp. (n=6). Among Gram-
negative isolates fermentative bacilli (n=104) were predominant as 
compared to non-fermentative bacilli (n=43). Out of all fermentative 
bacilli E. coli was predominant (n=67) followed by Klebsiella spp. (n=32) 
and K. oxytoca (n=5). In non-fermentative bacilli, Pseudomonas spp. 
(n=25) were more followed by Acinetobacter baumannii (n=18) 
(Table 2).
The most predominant IAIs were Peritonitis and Intestinal perforation 
in which most isolated organisms were E. coli followed by Klebsiella spp. 
and Pseudomonas spp. (Table 3).
The Anti-microbial susceptibility testing was also performed in 
which Imipenem was found to be the most effective drug among all 
Gram- negative isolates followed by Gentamicin except for Acinetobacter 
spp. in which the second most effective drug was Tigecycline (Table 4).
All the S. aureus (n=17) isolated were resistant to Cefoxitin, Penicillin 
and Oxacillin while highly sensitive to Vancomycin, Linezolid (100%) 
followed by Teicoplanin (85%). Among Enterococcus spp., Vancomycin 
and Linezolid (100%) were the most sensitive antibiotic followed by 
Teicoplanin (91%) (Table 5).
DISCUSSION
The emergence of resistance to routinely used antibiotics and even to 
newer antibiotics has made the treatment of IAIs a real challenge as a 
result accurate laboratory cultures for identification of organisms and 
their sensitivity testing has to be done with standard protocols. So that 
the microbiologists and physicians can go to decrease the mortality rate 
due to IAIs.
In the present study, Inpatient department (IPD) 405 (81%) patients 
were predominant over Outpatient department (OPD) 95 (19%) 
patients which are suspected IAIs (Table 1). This correlates with the 
study done by Jangla et al. which showed (76%) of the patients from 
IPDs and (24%) were from OPDs [12].
The rate of positivity from our study was 170/500 (34%) in which 
Gram-negative isolates (n=147) were dominating over Gram-positive 
isolates (n=23) (Table 2). Among the Gram-negative bacilli, the major 
isolates were of E. coli (n=67) followed by Klebsiella spp. (n=32), 
K. oxytoca (n=5) in fermenters and Pseudomonas spp. (n=25) followed 
by A. baumannii (n=18) in Non-fermenters. In Gram-positive isolates S. 
aureus (n=17) were more than Enterococcus spp. (n=6). These finding 
correlates with study done by Zhang et al. in which E. coli (47.3%) is 
the most common isolate obtained followed by Klebsiella spp. (17.2%), 
Pseudomonas spp. (10.1%), A. baumannii (8.3%), K. oxytoca (1.8%) [13]. 
Garg et al. conducted the same study and revealed that the E. coli (27.6%) 
is the most common isolate obtained in culture-positive samples 
of IAIs followed by Klebsiella spp. (16.9%), A. baumannii (12.5%), 
Pseudomonas spp. (8.9%) [5] (Table 3).
In the present study, Peritonitis (n=68) was found to be predominant 
clinical conditions followed by intestinal perforation (n=48) including 
Cholelithiasis (n=20), Appendicitis (n=15), Pancreatitis (n=10), and 
Liver abscess (n=9), respectively (Table 3). According to study done 
by Sukanya et al. peritonitis perforation (36.1%) was predominant 
clinical conditions followed by acute pancreatitis (11.7%) and necrotic 
pancreatitis (10%) [14].
The Anti-microbial susceptibility testing was also performed in 
which Imipenem was found to be most effective (E. coli- 92.5%, 
Klebsiella spp.- 93%, K. oxytoca- 91%, Pseudomonas spp.- 94% and 
A. baumanii- 88%) drug among all Gram negative isolates followed 
by Gentamicin (± 90%) except for A. baumanii in which second most 
effective drug was Tigecycline (82%) (Table 4). Similar results were 
found in study done by Shree et al. showed that the antibiotic resistance 
rate of Gram-negative isolates to Carbapenems, (Ertapenem – 29–41%) 
and (Meropenem – 14–15%) Imipenem, Tigecycline, and Colistin were 
most sensitive [15].
In the present study, all the S. aureus (n=17) isolated were resistant 
to Cefoxitin, Penicillin while highly sensitive to Linezolid (100%) 
(Table 5). Overall Enterococcus spp. was also found highly susceptible 
to Vancomycin and Linezolid (100%). In accordance of this Shree 
et al. also stated that S. aureus, higher resistance is shown to penicillin 
(91.7%), ciprofloxacin (58.4%), and gentamicin (33.3%) however, S. 
aureus is 100% sensitive to Vancomycin and Linezolid [15]. Similarly 
according to study done by Garg et al. revealed 100% sensitivity to 
Vancomycin and Linezolid, 91.66% to Amikacin and Clindamycin each, 
Cotrimoxazole 75%, Erythromycin 58.33%, and Ciprofloxacin 50% [5]. 
Table 2: Total samples showing growth and no growth in 











500 330 23 104 43
*Gram-positive Cocci, #Gram-negative Bacilli
Table 1: Distribution of patients from IPD and OPD included
Total no. of samples IPD OPD
500 405 (81%) 95 (19%)
IPD: Inpatient department, OPD: Outpatient department
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This study correlates with another study done by Liu et al. which 
showed 100% sensitivity to Vancomycin and Linezolid, while High-level 
resistant was shown in Penicillin (93.34%), Erythromycin (84.62%), 
and Ciprofloxacin (73.68%) [16].
CONCLUSION
The present study emphasizes the need for antimicrobial susceptibility 
testing of clinically significant isolates from IAIs as a routine practice. 
Knowing the prevalent pattern of antimicrobial resistance is an 
important issue especially when Gram-negative isolates continue to 
exhibit widespread resistance to various currently in use antimicrobial 
agents. Prompt starting of empirical antimicrobials based on the 
local susceptibility pattern, followed by modification of treatment in 
accordance with the antimicrobial susceptibility report which can 
significantly reduce the morbidity and the mortality associated with 
IAIs.
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